Diego Ripamonti

Diego Ripamonti

UNVERIFIED PROFILE

Are you Diego Ripamonti?   Register this Author

Register author
Diego Ripamonti

Diego Ripamonti

Publications by authors named "Diego Ripamonti"

Are you Diego Ripamonti?   Register this Author

57Publications

596Reads

25Profile Views

Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from dual therapy studies.

AIDS 2018 04;32(7):835-840

Department of Medical Biotechnology, University of Siena, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000001776DOI Listing
April 2018

Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?

AIDS Res Hum Retroviruses 2018 02 18;34(2):168-170. Epub 2018 Jan 18.

1 Infectious Diseases Unit, Policlinico Ospedale San Martino, University of Genoa , Genoa, Italy .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/AID.2017.0112DOI Listing
February 2018

Autoimmune hepatitis and HIV infection: two case reports and review of the literature.

AIDS 2017 Sep;31(15):2172-2175

aDepartment of Clinical and Experimental Medicine, Clinic of Infectious Diseases, University of Foggia, Foggia bDivision of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000001608DOI Listing
September 2017

Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.

Clin Infect Dis 2017 05;64(9):1198-1203

Department of Pharmacology, Oates Institute for Experimental Therapeutics, Vanderbilt University Medical School, Nashville, Tennessee, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/cix096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399947PMC
May 2017

Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infection.

Authors:
Diego Ripamonti

Evid Based Med 2016 10 26;21(5):184. Epub 2016 Aug 26.

Infectious Diseases Unit, Azienda Ospedaliera Papa Giovanni XXIII, Piazza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ebmed-2016-110464DOI Listing
October 2016

Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues.

AIDS 2015 Sep;29(14):1811-20

aNational Institute for Infectious Diseases, L. Spallanzani IRCCS, Rome, Italy bBrighton and Sussex University Hospitals, Brighton, UK cKarolinska University, Sjukhuset, Sweden dHospital Universitario La Paz, IdiPAZ, Madrid, Spain eMedical Research Council, HIV Clinical Trials Unit, London, UK fDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland gCopenhagen University Hospital, Copenhagen, Denmark hWarsaw Medical University, Infectious Diseases, Warsaw, Poland iUniversity Hospital Germans Trias I Pujol, irsiCaixa, Badalona, Spain jInfectious Diseases, Ospedale Papa Giovanni XXIII, Bergamo, Italy kDepartment of Infectious and Tropical Diseases, Hôpital Saint-Antoine, AP-HP, and INSERM UMR S 1136, Paris, France lUniversity of Liverpool, Liverpool, UK mJanssen, EMEA, Neuss, Germany.

View Article

Download full-text PDF

Source
http://www.natap.org/2015/HIV/Week_48_efficacy_and_central_n
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/QAD.0000000000000778DOI Listing
September 2015

Brain abscess.

N Engl J Med 2014 10;371(18):1756-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1410501DOI Listing
October 2014

Do lopinavir and ritonavir require a dose adjustment during pregnancy?

J Acquir Immune Defic Syndr 2014 Jul;66(3):e64-5

*Infectious Diseases Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy †Clinical Pharmacology Unit, Azienda Ospedaliera Luigi Sacco, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAI.0000000000000155DOI Listing
July 2014

Abacavir-induced liver toxicity in an HIV-infected patient.

AIDS 2014 Feb;28(4):613

Department of Infectious Disease, Papa Giovanni XXIII° Hospital, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000000139DOI Listing
February 2014

Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor.

Expert Rev Anti Infect Ther 2014 Jan 28;12(1):13-29. Epub 2013 Nov 28.

Infectious Diseases Unit, Ospedale Papa Giovanni XXIII, Piazza OMS 1 (BG), 24127, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14787210.2014.863708DOI Listing
January 2014

Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.

Fundam Clin Pharmacol 2013 Apr 2;27(2):216-22. Epub 2011 Nov 2.

CNR Institute of Neuroscience and Unit of Clinical Pharmacology, Department of Clinical Sciences, Luigi Sacco University Hospital, Università di Milano, via GB Grassi 74, 20157 Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1472-8206.2011.01005.xDOI Listing
April 2013

Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.

Drugs 2012 Jun;72(9):1161-73

Department for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/11631070-000000000-00000DOI Listing
June 2012

Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.

J Clin Pharmacol 2012 Mar 7;52(3):440-5. Epub 2011 Mar 7.

Unit of Clinical Pharmacology, Luigi Sacco University Hospital, via GB Grassi 74, 20157 Milano, Italy.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1177/0091270010395939
Publisher Site
http://dx.doi.org/10.1177/0091270010395939DOI Listing
March 2012

Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.

Ther Drug Monit 2010 Dec;32(6):782-6

Unit of Clinical Pharmacology, Department of Clinical Sciences, Luigi Sacco University Hospital, Università di Milano, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0b013e3181fa53b7DOI Listing
December 2010

Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3.

Curr HIV Res 2010 Apr;8(3):186-93

Servizio Biometria ed Epidemiologia Clinica - Direzione Scientifica - Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157016210791111070DOI Listing
April 2010

Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.

Curr Opin Investig Drugs 2008 Aug;9(8):899-912

Malattie Infettive, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy.

View Article

Download full-text PDF

Source
August 2008

Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection.

J Chromatogr Sci 2008 Jul;46(6):485-9

Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo - Mario Negri Institute for Pharmacological Research, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/chromsci/46.6.485DOI Listing
July 2008

Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort.

J Antimicrob Chemother 2007 Mar 25;59(3):569-72. Epub 2007 Jan 25.

Divisione di Malattie Infettive, Ospedali Riuniti, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkl534DOI Listing
March 2007

The Trivacan study.

Lancet 2006 Sep;368(9539):915; author reply 916

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(06)69364-1DOI Listing
September 2006

Quadruple-drug induction HAART in advanced HIV infection.

HIV Clin Trials 2005 Jan-Feb;6(1):1-4

Division of Infectious Diseases, Antiviral Therapy Unit, Ospedali Riuniti di Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1310/LBGE-NMMX-CE1A-AK0YDOI Listing
June 2005

Switch strategies in patients on effective HAART.

J Antimicrob Chemother 2005 Jun 22;55(6):821-3. Epub 2005 Apr 22.

Division of Infectious Diseases, Ospedali Riuniti, Largo Barozzi 1, Bergamo 24128, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dki119DOI Listing
June 2005

Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.

Clin Infect Dis 2005 Jan 6;40(1):158-63. Epub 2004 Dec 6.

Division of Infectious Diseases, Unit of Antiviral Therapy, Ospedali Riuniti, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/426595DOI Listing
January 2005

New times for an old disease: intracranial mass lesions caused by Mycobacterium tuberculosis in 5 HIV-negative African immigrants.

Clin Infect Dis 2004 Sep 11;39(5):e35-45. Epub 2004 Aug 11.

Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/422876DOI Listing
September 2004

Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial.

AIDS 2004 Feb;18(3):439-46

Division of Infectious Diseases and the Microbiology and Virology Laboratory, Ospedali Riuniti, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00002030-200402200-00010DOI Listing
February 2004

Hepatitis C infection increases the risk of the modification of first highly active antiretroviral therapy in HIV-infected patients.

AIDS 2004 Jan;18(2):334-7

Antiviral Therapy Unit, Infectious Diseases Department, Ospedali Riuniti di Bergamo, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00002030-200401230-00028DOI Listing
January 2004

Once-a-day HAART: dream or reality?

HIV Clin Trials 2003 May-Jun;4(3):193-201

Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1310/1ger-1qjg-wdxm-489uDOI Listing
August 2003

Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection.

Clin Infect Dis 2003 Jul 23;37(1):41-9. Epub 2003 Jun 23.

Division of Infectious Diseases, Ospedali Riuniti, 24128 Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/375598DOI Listing
July 2003

Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients.

HIV Clin Trials 2002 Sep-Oct;3(5):371-8

Divisione di Malattie Infettive, Ospedali Riuniti, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1310/98b3-pwg8-pmyw-w5bpDOI Listing
January 2003

Factors associated with the failure of HIV-positive persons to return for scheduled medical visits.

HIV Clin Trials 2002 Jan-Feb;3(1):52-7

Unità Operativa di Malattie Infettive, Ospedali Riuniti di Bergamo, Largo Barozzi, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1310/2XAK-VBT8-9NU9-6VAKDOI Listing
April 2002

African sleeping sickness in tourists returning from Tanzania: the first 2 Italian cases from a small outbreak among European travelers.

Clin Infect Dis 2002 Jan 19;34(1):E18-22. Epub 2001 Nov 19.

Infectious Diseases Unit, General Hospital of Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/338157DOI Listing
January 2002